Sign In
Buy ASND
$216.79
+0.190 (+0.0877%)
At Close: Jun 03, 2026
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
12:16am, Thursday, 28'th May 2026
Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth,
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
01:01am, Saturday, 09'th May 2026
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Ascendis Pharma Reports First Quarter 2026 Financial Results
07:30am, Thursday, 07'th May 2026
- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL ®
COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age a
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
04:01pm, Thursday, 30'th Apr 2026
COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thur
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
04:31pm, Tuesday, 21'st Apr 2026
COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Con
Assetmark Inc. Has $1.83 Million Stake in Ascendis Pharma A/S $ASND
03:24am, Tuesday, 21'st Apr 2026
Assetmark Inc. raised its holdings in Ascendis Pharma A/S (NASDAQ: ASND) by 48.1% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,579 sh
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
08:00am, Monday, 20'th Apr 2026
COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
12:00pm, Wednesday, 08'th Apr 2026
- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq
- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
04:01pm, Monday, 06'th Apr 2026
- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses
Braun Stacey Associates Inc. Buys 25,148 Shares of Ascendis Pharma A/S $ASND
04:35am, Sunday, 05'th Apr 2026
Braun Stacey Associates Inc. grew its stake in Ascendis Pharma A/S (NASDAQ: ASND) by 26.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission
Allspring Global Investments Holdings LLC Has $40.02 Million Stock Position in Ascendis Pharma A/S $ASND
03:09am, Friday, 03'rd Apr 2026
Allspring Global Investments Holdings LLC lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ: ASND) by 2.1% during the undefined quarter, according to the company in its most recent disclo
Ascendis Pharma A/S (NASDAQ:ASND) Share Price Crosses Above Fifty Day Moving Average – Should You Sell?
04:33am, Wednesday, 01'st Apr 2026
Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report)'s share price passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $227.04 and traded as high
- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children - TransCon hGH showed a safety and tolerability p
